Skip to main content
2025 ASCRS Annual Scientific Meeting Main banner
Final Program


Visit ASCRS U
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Self-Assessment
Self-Assessment
Social
Social
Industry
Industry
Back

Session: ePoster: Colon and Colorectal Cancer 4 (Sun1230)

EP432 - 1st line treatment strategies in BRAF-V600E mutation mCRC patients: a clinical experience and real-world data from a single center

Sunday, May 11, 2025
12:35 PM – 12:40 PM PT
Location: Monitor 5, Sails Pavilion, Upper Level

    ePoster Presenter(s)

  • Chia-Chang Yeh (he/him/his)

    Residency
    Division of Colorectal cancer,Department of surgery, Taichung Veterans General Hospital, Taichung, Taiwan
    Taichung, Taichung, Taiwan (Republic of China)

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

    • Senior Author(s)

  • FC

    Feng-Fan Chiang, Colorectal surgeon

    Attending physician
    Division of Colorectal cancer,Department of surgery, Taichung Veterans General Hospital, Taichung, Taiwan
    Taichung, Taichung, Taiwan (Republic of China)

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

    • Author(s)

  • SC

    Shih-Wei Chiang, Colorectal surgeon

    Attending physician
    Division of Colorectal cancer,Department of surgery, Taichung Veterans General Hospital, Taichung, Taiwan
    Taichung, Taichung, Taiwan (Republic of China)

    Disclosure information not submitted.

All of the relevant financial relationships listed below have been mitigated.
Chia-Chang Yeh: This individual has no financial relationships with ineligible companies.
Feng-Fan Chiang, Colorectal surgeon: This individual has no financial relationships with ineligible companies.
Image or Table (Do Not add text here):

Purpose/Background: BRAFV600E mutations are present in 8%-12% of metastatic colorectal cancer (mCRC) cases and are linked to poor survival outcomes. European guidelines recommend first-line treatment with combination chemotherapy (either doublet or triplet) plus bevacizumab. Despite this, there remains a significant unmet need for more effective therapies for these patients.

Methods/Interventions: This retrospective, single-center observational study in Taiwan evaluates real-world treatment practices for patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) treated between January 1, 2018, and January 31, 2024. The primary objective was to describe first-line treatment patterns, while the secondary objectives included an analysis of baseline demographics, treatment effectiveness, and safety outcomes.

Results/Outcomes: A total of 31 patients (median age 56.3 years; 41.9% female) with BRAFV600E-mutant unresectable metastatic colorectal cancer (mCRC) from Taichung Veterans General Hospital were included in the study. A high proportion (61.3%) had left-sided tumors, and 25.8% presented with peritoneal and multiple metastatic disease at diagnosis. First-line treatment favored chemotherapy plus targeted therapy (46.7%) over chemotherapy alone (26.7%), with the emerging use of BRAF inhibitors combined with anti-EGFR therapy ± anti-MEK inhibitors (26.7%). The median duration of first-line treatment was 7.2 months, and 56.7% of patients went on to receive second-line treatment. Across all first-line regimens, progression-free survival (PFS) was 9.5 months [95% confidence interval (CI) 6.2-12.8], and overall survival (OS) was 18.2 months [95% CI 13.2-23.3].

Conclusion/Discussion: This study represents the real-world analysis to date of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), offering valuable insights into routine first-line treatment practices. The findings underscore the aggressive nature of this disease subgroup, reinforcing results from previous real-world studies and clinical trials, and emphasizing the urgent need for more effective treatment options in this setting.